This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    31/07/17

    Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

    The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma...

    • Source: British Journal of Haematology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    15/07/15

    Takeda files NDA at FDA for ixazomib to treat multiple myeloma

    Takeda announced that a New Drug Application (NDA) has been submitted to the FDA for ixazomib, an investigational oral proteasome...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/04/17

    NICE does not recommend Ninlaro (ixazomib) combination + lenalidomide + dexamethasone as a treatment for multiple myeloma.-Takeda

    The National Institute for Health and Care Excellence (NICE), in a draft recommendation, has rejected Ninlaro (ixazomib) combination with lenalidomide...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/12/21

    Takeda provides update on TOURMALINE-MM2 phase III trial of ixazomib + lenalidomide + dexamethasone to treat transplantation ineligible multiple myeloma patients.

    Takeda Pharmaceutical Company Limited announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of Ninlaro (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/11/15

    FDA approves Ninlaro (ixazomib) + lenalidomide + dexamethasone oral combination to treat multiple myeloma- Takeda

    Takeda Pharmaceutical Company Limited has announced that the FDA has approved Ninlaro (ixazomib) capsules, the first and only oral proteasome...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/11/16

    EU approves Ninlaro (ixazomib) capsules in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma- Takeda

    Takeda Pharmaceutical has announced that the European Commission has granted conditional marketing authorization for Ninlaro (ixazomib) capsules, indicated in combination...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/07/12

    Ixazomib (Takeda/Millennium) enters Phase III trials for Multiple Myeloma

    Takeda and Millennium Oncology have begun a Phase III development programme for ixazomib citrate (MLN 9708), the first oral proteasome...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/12/15

    Phase III trial of Ninlaro (ixazomib) + lenalidomide + dexamethasone demonstrates improved survival in multiple myeloma- Takeda

    Takeda has announced results from the TOURMALINE-MM1, an international, randomized, double-blind, placebo-controlled Phase III clinical trial, showing that treatment with...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/08/15

    EMA accepts application (MAA) for ixazomib to treat relapsed and/or refractory multiple myeloma- Takeda

    Takeda Pharmaceutical Company Limited announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for ixazomib,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/02/15

    Success for ixazomib in TOURMALINE-MM1 pivotal Phase III trial for Multiple Myeloma- Takeda

    Takeda Pharmaceutical Company Limited announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase III trial evaluating the safety and efficacy...

    See more